Cargando…
Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
SIMPLE SUMMARY: Immunotherapy has been positioned as frontline therapy for advanced non-small cell lung cancer (NSCLC), alone when PD-L1 tumor expression is high, or combined with chemotherapy otherwise. However, 50% of the patients do not respond to the treatment and the mechanisms of resistance ar...
Autores principales: | Arasanz, Hugo, Bocanegra, Ana Isabel, Morilla, Idoia, Fernández-Irigoyen, Joaquín, Martínez-Aguillo, Maite, Teijeira, Lucía, Garnica, Maider, Blanco, Ester, Chocarro, Luisa, Ausin, Karina, Zuazo, Miren, Fernández-Hinojal, Gonzalo, Echaide, Miriam, Fernández-Rubio, Leticia, Piñeiro-Hermida, Sergio, Ramos, Pablo, Mezquita, Laura, Escors, David, Vera, Ruth, Kochan, Grazyna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406164/ https://www.ncbi.nlm.nih.gov/pubmed/36010840 http://dx.doi.org/10.3390/cancers14163846 |
Ejemplares similares
-
CAR-T Cells for the Treatment of Lung Cancer
por: Chocarro, Luisa, et al.
Publicado: (2022) -
Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021) -
Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021) -
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023) -
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
por: Arasanz, Hugo, et al.
Publicado: (2020)